Clinical trial supplies specialist discusses streamlining their operations
For Clinical Trial Supply organizations, being fleet of foot is essential. The recent pandemic has seen additional pressures placed on the supply chain, as drug shortages and patient recruitment have proved problematic for many companies.
Rhys Evans, Senior Director of CTS and Global Supply at RxSource, presents a case study on how his team implemented a cloud-based label management solution rapidly to optimize the company’s demand-led secondary packaging and labelling services, allowing them to supply medicines faster.
The company, who specialize in the ethical sourcing, packaging and delivery of medicines for Clinical Trials, Research & Development and Expanded Access Programs, implemented the PRISYM 360 platform in a matter of weeks. It now enables RxSource to produce labels, package and supply medicines in as little as 48 hours.
In this 60-minute, information-packed session, RxSource and PRISYM ID explore the key areas to optimizing your labelling and packaging processes.
Presented by
Rhys Evans,
Senior Director, CTS and Global Supply at RxSource
Rhys Evans is the Senior Director of CTS and Global Supply at RxSource where he oversees the Commercial Team and strategic growth of clinical trial services.
Rhys has worked in the clinical trial services arena for over 8 years and has a passion for exploring ways to streamline the supply chain to accelerate patients access to medicines without compromising on quality. Rhys has a PhD in Respiratory Pharmacology and a First-Class Honours Degree in Applied Physiology and Pharmacology.
In addition to working for RxSource, Rhys is a member of the Global Clinical Supplies Group Committee.
Steve Ellison,
VP of Global Clinical Trials
Steve has spent over 24 years working with coding and labeling solutions and for the last five years he has been promoting the PRISYM ID’s world-class labeling solutions.
During his time with PRISYM ID, he has observed many changes within the life science industry including significant tightening of regulations, the challenges of globalization and the implementation of directives.
He has successful working relationships with a diverse spectrum of market leading companies in medical device, pharmaceutical, healthcare and clinical trial sectors.